In patients with advanced epithelial ovarian cancer, first-line maintenance therapy with PARP inhibitors was associated with a progression-free survival benefit compared with standard chemotherapy ...

Poly(ADP-ribose) polymerase (PARP) inhibitors should be considered a treatment option for patients with uterine leiomyosarcomas harboring BRCA2 deep deletions, researchers advised. PARP inhibitors are ...

PARP inhibitors are generating a lot of excitement in the field of ovarian cancer. But how, exactly, do they work? CURE spoke with one expert to find out.

A new study introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients.

Nearly half of advanced ovarian cancer patients relapsed after first-line PARP inhibitor maintenance, emphasizing the need for refined postrecurrence strategies. BRCA mutation carriers were more ...

SAN DIEGO -- Saruparib, an investigational selective PARP1 inhibitor, showed promising activity in patients with certain homologous recombination repair (HRR)-deficient breast cancers, while limiting ...

Poly (ADP-ribose) polymerase 1 (PARP-1) plays a crucial role in DNA repair and represents the pivotal target for first-generation PARP inhibitors.

Please provide your email address to receive an email when new articles are posted on . Nearly half of men with metastatic castration-resistant prostate cancer eligible for PARP inhibitors do not get ...

AstraZeneca and Merck & Co. were the first to grab an FDA approval for their PARP inhibitor Lynparza, and, despite growing competition, the drug is set to remain top dog in the PARP space. That’s ...